Related Experiment Videos
Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex
1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Mayo Medical School, Rochester, MN 55905, USA.
Neurobiology of Aging
|August 21, 2003
Summary
Acetylcholinesterase (AChE) may accelerate Alzheimer's disease progression. In vivo studies showed that combining AChE and amyloid precursor protein genes in mice led to earlier and more abundant amyloid plaque formation.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- In vitro studies suggest acetylcholinesterase (AChE) interacts with beta-amyloid, potentially promoting Alzheimer's disease (AD) plaques.
- Understanding this interaction in vivo is crucial for AD pathogenesis research.
Purpose of the Study:
- To investigate the in vivo role of acetylcholinesterase (AChE) in the development of amyloid plaques.
- To determine if AChE accelerates amyloid deposition in a mouse model of Alzheimer's disease.
Main Methods:
- Crossed Tg2576 mice (human amyloid precursor protein) with transgenic mice expressing human AChE.
- Analyzed F1 hybrids for amyloid plaque formation, onset, and quantity using immunohistochemistry and ELISA.
- Examined plaque composition for markers like beta-amyloid, Cd11b, GFAP, and AChE.
Main Results:
- Doubly transgenic mice exhibited authentic amyloid plaques by 6 months of age.
- Plaque onset was 30-50% earlier in hybrids compared to parental lines.
- Hybrid mice showed increased plaque numbers and total brain amyloid content at 9-12 months.
Conclusions:
- In vivo results support the hypothesis that AChE contributes to Alzheimer's disease pathogenesis.
- AChE may play a significant role in the acceleration of amyloid plaque deposition.
- This study provides evidence for AChE as a potential therapeutic target in Alzheimer's disease.